Kiniksa (KNSA) insider filing: 10b5-1 plan trades by CFO Ragosa

Rhea-AI Filing Summary

Report: Form 4 filed for Ragosa Mark (address: 23 Old Bond Street, London) reporting transactions in Kiniksa Pharmaceuticals International, plc (KNSA). The reporting person is identified as a Director and Chief Financial Officer. Earliest transaction date: 08/04/2025. Form signed by Madelyn Zeylikman, Attorney-in-Fact, dated 08/06/2025.

Transactions: Table I shows two Class A Ordinary Share transactions on 08/04/2025 involving 18,889 shares at prices of $22.89 and $32.89, with reported post-transaction beneficial ownerships of 45,898 and 27,009. Table II reports a Share Option with exercise/conversion price $22.89 covering 18,889 underlying Class A shares, expiration 03/15/2031, and 2,036 derivative securities reported beneficially owned following the transaction. The filing states the transactions were effected pursuant to a 10b5-1 plan executed Sept 3, 2024 and discloses the option vesting schedule (vesting commencement 03/16/2021; 25% on first anniversary; monthly vesting over 36 months).

Positive

• Transactions disclosed under a 10b5-1 plan, enhancing transparency about timing and intent.
• Vesting schedule and option expiration are explicitly disclosed (vesting commencement 03/16/2021; expiration 03/15/2031).

Negative

• Reported change in holdings includes 18,889 shares referenced and a post-transaction beneficial ownership level of 27,009 shares, indicating a notable shift in reported holdings.

Insights

Financial Analyst

TL;DR: Insider transactions executed under a 10b5-1 plan; disclosed share and option changes appear routine and documented.

The Form 4 reports two Class A Ordinary Share-related transactions and a related share option on 08/04/2025. Key numeric disclosures include 18,889 shares referenced twice at prices of $22.89 and $32.89, post-transaction beneficial ownerships of 45,898 and 27,009, and 2,036 derivative securities reported following the transaction. The filing explicitly states the trades were effected pursuant to a 10b5-1 plan executed Sept 3, 2024, which limits the immediate informational content regarding intent. For investors, the primary actionable facts are the magnitudes of the reported share and option activity and the disclosed vesting timetable.

Corporate Governance Expert

TL;DR: Filing shows compliance with Section 16 disclosures and documents a 10b5-1 plan and vesting schedule.

The submission includes signature by an attorney-in-fact and cites the 10b5-1 plan date, satisfying common procedural transparency expectations for executive trades. It provides explicit vesting terms for the option (commencement 03/16/2021; 25% after one year; remaining vest monthly over 36 months) and an expiration date of 03/15/2031. From a governance perspective, the filing contains the standard elements: reporting person identity and role (Director and CFO), transaction dates, volumes, prices, and the plan reference. No additional governance or compliance exceptions are stated in the document.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ragosa Mark

(Last) (First) (Middle)

23 OLD BOND STREET, THIRD FLOOR

(Street)

LONDON X0 W1S 4PZ

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Kiniksa Pharmaceuticals International, plc [ KNSA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
08/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Share	08/04/2025		M(1)		18,889	A	$22.89	45,898	D
Class A Ordinary Share	08/04/2025		S(1)		18,889	D	$32.89	27,009	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option	$22.89	08/04/2025		M(1)			18,889	(2)	03/15/2031	Class A Ordinary Share	18,889	$0	2,036	D

Explanation of Responses:

1. This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024.

2. The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is March 16, 2021.

	/s/ Madelyn Zeylikman, Attorney-in-Fact	08/06/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the KNSA Form 4 filed on 08/06/2025 disclose?

The filing discloses transactions dated 08/04/2025 by Ragosa Mark (CFO/Director) involving 18,889 share-related items and a related option, and was signed 08/06/2025.

Were the transactions for Kiniksa (KNSA) executed under a trading plan?

Yes. The Form 4 states the transactions were effected pursuant to a 10b5-1 plan executed Sept 3, 2024.

How many shares and at what prices are shown on the Form 4 for KNSA?

The form references 18,889 shares at prices of $22.89 and $32.89, with reported post-transaction beneficial ownerships of 45,898 and 27,009.

Does the filing include option details for KNSA?

Yes. A Share Option with an exercise/conversion price of $22.89 covering 18,889 underlying Class A shares is reported, with expiration 03/15/2031 and stated vesting terms.

Who signed the Form 4 and when?

The Form 4 is signed by Madelyn Zeylikman, Attorney-in-Fact, dated 08/06/2025.